Abstract
Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37.5 days during remission-induction therapy and 3.7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Rees, J., Sandler, R., Challener, J. et al. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: dat. Br J Cancer 36, 770–776 (1977). https://doi.org/10.1038/bjc.1977.260
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.260
This article is cited by
-
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside
Cancer Chemotherapy and Pharmacology (1987)
-
Uptake of adriamycin by human leukemic cells as measured by flow cytometry
Medical Oncology and Tumor Pharmacotherapy (1984)
